
AOA Dx
AOA Dx is a YC Summer 2021 (S21) company. Based in Denver, CO, USA; Cambridge, MA, USA. Team of 25.
About AOA Dx
Summary
AOA Dx develops blood-based tests for early-stage ovarian cancer detection in women. Its AKRIVIS GD platform combines multi-omics biomarkers, including glycolipid and lipidomic markers, with AI to identify cancer at a stage when it is most treatable. The product targets the diagnostic gap currently filled by imaging and invasive procedures that catch ovarian cancer late.
Go-to-market
AOA Dx targets healthcare providers and patients, bringing its diagnostic technology from R&D into clinical use through direct engagement with the medical community.
From the Y Combinator listing
Blood Test for Early Detection of Ovarian Cancer
AOA Dx is developing the next frontier in early-stage cancer detection for women through our pioneering work in glycolipids and proprietary biomarker technology.
Facts
- Healthcare / Healthcare -> Diagnostics
- Denver, CO, USA; Cambridge, MA, USA
- 25
- Active
- Early
Founders (3)
- Alex Fisher
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works